by Elana Gotkine Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according to a study published online Oct. 25 in the New England Journal of Medicine to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held from...
Tag: <span>Empagliflozin</span>
Post
Empagliflozin may decrease risk of kidney stones in people with diabetes
THE ENDOCRINE SOCIETY The diabetes drug empagliflozin may decrease the risk of kidney stones in patients with type 2 diabetes, according to a new study presented Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga. Diabetes is a well-known risk factor for kidney stones. Empagliflozin (Jardiance) is an SGLT2 inhibitor....